GlassScriptPhysician profile
Alena Polesin
NPI 1679686893
$3,417.86
in general payments reported to CMS, 2019-2025
28 companies · $561 in 2025
The $561 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $279 · 2021: $506 · 2022: $817 · 2023: $536 · 2024: $718 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,814.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $997.87 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $544.66 | 2021-2025 | Xtampza |
| Arbor Pharmaceuticals, INC. | $217.13 | 2021-2022 | |
| Horizon Therapeutics Plc | $190.77 | 2020-2021 | |
| Almatica Pharma LLC | $187.35 | 2022-2023 | Gralise |
| Ibsa Pharma INC. | $166.34 | 2021-2025 | Licart, Tirosint, Flector |
| Medtronic, INC. | $153.77 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Allergan, INC. | $112.67 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $112.58 | 2023-2025 | Horizant, Horizant |
| Teva Pharmaceuticals USA, INC. | $74.17 | 2021-2022 | |
| Amgen INC. | $72.72 | 2021-2022 | |
| Lilly USA, LLC | $69.75 | 2020-2022 | |
| Bioventus LLC | $64.84 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $64.13 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $62.16 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $48.14 | 2021-2025 | Prolate, Tanlor, Nalocet |
| Electronic Waveform Lab, INC. | $38.29 | 2023-2025 | |
| Fidia Pharma USA INC. | $33.18 | 2023-2025 | Hymovis, Triluron |
| Terumo Bct, INC. | $31.25 | 2020 | |
| Nevro Corp. | $29.61 | 2024 | Senza |
| Ultragenyx Pharmaceutical INC. | $29.08 | 2020-2022 | |
| Abbott Laboratories | $23.88 | 2022 | |
| Medline Industries LP | $18.50 | 2023 | |
| Virtus Pharmaceuticals LLC | $16.88 | 2025 | Levorphanol Tartrate |
| Depuy Synthes Sales INC. | $16.35 | 2023 | Orthovisc |
| Redhill Biopharma INC. | $15.20 | 2020 | |
| Pfizer INC. | $14.55 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alena Polesin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.